Paul Perreault, CSL Behring's chief executive (file photo)
In an unexpected twist, CSL buys worldwide rights to uniQure's PhIII hemophilia B gene therapy in $2B-plus deal
In a surprise move, CSL Behring reported after the market closed on Wednesday that it is acquiring uniQure’s Phase III hemophilia B gene therapy with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.